Clinical Trial Applications - Approved: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | Date Approved | |
|---|---|---|---|---|---|
11. |
ECCT/25/12/04 | Floral Study An open-label, multi-centre, rollover study to characterise long-term safety and efficacy of etavopivat in adults, adolescents and children who have sickle cell disease or thalassaemia and have completed a treatment period in an etavopivat study |
Principal Investigator(s) 1. Walter Otieno Site(s) in Kenya 1. Kombewa Clinical Research Center (Kisumu county) 2. KEMRI Kondele Children\'s Hospital (Kisumu county) 3. Center for Research in Therapeutic Sciences (CREATES) (Kisumu county) 4. KEMRI Siaya Clinical Research Annex (Siaya county) 5. KEMRI WALTER REED KERICHO (Kericho county) 6. Getrude\'s Children\'s Hospital (Nairobi City county) |
13-04-2026 |
View |
12. |
ECCT/25/12/01 | Accetability testing Study Assessing the acceptability of enhanced multiple micronutrient supplements among pregnant women in Bungoma County |
Principal Investigator(s) 1. Zipporah Nekesa Bukania Site(s) in Kenya Tongaren Subcounty, Bungoma County |
14-07-2026 |
View |
13. |
ECCT/25/11/07 | MK-8527 as HIV-1 PrEP Protocol Title: A Phase 3, Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy and Safety of MK-8527 Oral Once-Monthly as HIV-1 Preexposure Prophylaxis |
Principal Investigator(s) 1. John Mark Ayallo 2. Kelvin Jerry Wandera 3. John Okanda 4. Joash Diemo 5. Tobias Odwar 6. Jacob Onyango Site(s) in Kenya 1. Kenya Impact Research and Development Organization (K-IRDO) (Kisumu county) 2. Nyanza Reproductive Health Society (NRHS), UNIM Research and Training Center (URTC) (Kisumu county) 3. Partners for Health and Development in Africa – Sex workers Outreach Program (PHDA – SWOP) (Nairobi City county) |
09-02-2026 |
View |
14. |
ECCT/25/11/06 | MK-8527-011 Study A Phase 3, Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy and Safety of MK-8527 Oral Once-Monthly as HIV-1 Preexposure Prophylaxis |
Principal Investigator(s) 1. Dr Maricianah Onono Site(s) in Kenya 1. Nyanza Reproductive Health Society (NRHS), UNIM Research and Training Centre (URTC) (Kisumu county) 2. Kenya Impact Research and Development Organization (K-IRDO) (Kisumu county) 3. Partners for Health and Development in Africa – Sex workers Outreach Program (PHDA – SWOP) Clinic- Nairobi, Kenya (Nairobi City county) |
05-03-2026 |
View |
15. |
ECCT/25/11/05 | MK-8527-011 Study A Phase 3, Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy and Safety of MK-8527 Oral Once-Monthly as HIV-1 Preexposure Prophylaxis |
Principal Investigator(s) 1. Dr. Joshua Kimani Site(s) in Kenya 1. Nyanza Reproductive Health Society (NRHS), UNIM Research and Training Centre (URTC) (Kisumu county) 2. Partners for Health and Development in Africa – Sex workers Outreach Program (PHDA – SWOP) Clinic- Nairobi, Kenya (Nairobi City county) 3. Kenya Impact Research and Development Organization (K-IRDO) (Kisumu county) |
05-03-2026 |
View |
16. |
ECCT/25/11/04 | Bifin02 and LGG® A Phase 3, randomized, double-blind, placebo-controlled trial to evaluate the effect of Bifidobacterium longum subsp. infantis DSM33361(Bifin02) administered together with Lacticaseibacillus rhamnosus GG DSM33156 (LGG®) versus placebo on weight gain in underweight infants |
Principal Investigator(s) 1. Charity Wambui Kanyoro Site(s) in Kenya 1. Moi University Clinical Research (Uasin Gishu county) 2. Kenya Medical Research Institute (KEMRI) CRDR Off Raila Odinga, Nairobi Kenya (Nairobi City county) 3. Kenya Medical Research Institute (KEMRI) Mwtapa (Kilifi county) |
19-08-2026 |
View |
17. |
ECCT/25/11/03 | RSV IMPACT TRIAL A Phase-IIIb individually randomized, placebo-controlled trial on safety of RSVA/B-preF vaccine in pregnant women and efficacy against severe RSV-associated lower respiratory tract infection in infants. |
Principal Investigator(s) 1. Nancy A. Otieno 2. Evans M. Ogoti Site(s) in Kenya Kenya Medical Research Institute, Centre for Global Health Research - Siaya (KE1) |
09-02-2026 |
View |
18. |
ECCT/25/11/02 | DELIVER-02 IGHID 12430/DELIVER-02 - A PHASE 1, OPEN LABEL,STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF MGD014 AND MGD020 WITH A LATENCY REVERSAL AGENT VERSUS TEMPORARY TREATMENT INTERRUPTION IN PERSONS WITH HIV-1 ON ANTIRETROVIRAL THERAPY |
Principal Investigator(s) 1. Deborah Chepngeno Langat Site(s) in Kenya 1. Kericho Clinical Research Center (Kericho CRC), Kericho, (Kericho county) 2. MOI UNIVERSITY CLINICAL RESEARCH CENTRE (MUCRC), ELDORET (Uasin Gishu county) |
25-06-2026 |
View |
19. |
ECCT/25/11/01 | COMBO-CONSTELLATION A Phase 3, randomized, double-blind, placebo-controlled trial to evaluate the effect of Bifidobacterium longum subsp. infantis DSM33361(Bifin02) administered together with Lacticaseibacillus rhamnosus GG DSM33156 (LGG®) versus placebo on weight gain in underweight infants |
Principal Investigator(s) 1. Dr. Wilson Muraya Site(s) in Kenya 1. KENYA MEDICAL RESEARCH INSTITUTE- MTWAPA (Kilifi county) 2. Moi University Clinical Research Centre-MUCRU (Uasin Gishu county) 3. Kenya Medical Research Institute (KEMRI) CRDR (Nairobi City county) |
21-06-2026 |
View |
20. |
ECCT/25/10/01 | H06_04TP A Phase 2, open-label, single-center, long-term immunogenicity follow-up study of the GVGH altSonflex1-2-3 Shigella vaccine 1, 2 and 3 years after vaccination in African children. |
Principal Investigator(s) 1. Deborah Chepngeno Langat Site(s) in Kenya KEMRI CRC WRP KERICHO |
01-02-2026 |
View |